bioAffinity Showcases CyPath Lung at Cleveland Clinic
SAN ANTONIO, Texas, United States, April 7, 2026 bioAffinity Technologies, Inc. announced that its CyPath® Lung diagnostic test will...
ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody NSCLC Oncology oncology innovation oncology research Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
SAN ANTONIO, Texas, United States, April 7, 2026 bioAffinity Technologies, Inc. announced that its CyPath® Lung diagnostic test will...
SAN ANTONIO, TX, March 17, 2026 bioAffinity Technologies, Inc. has released a new clinical case study demonstrating how its...
FRANKLIN LAKES, N.J., Feb. 9, 2026 — Becton, Dickinson and Company (BD) announced the successful completion of the previously...
